Randomized phase III trial of intravenous and intraperitoneal paclitaxel with S-1 versus gemcitabine plus nab-paclitaxel for pancreatic ductal adenocarcinoma with peritoneal metastasis (SP study)
AbstractThe prognosis of pancreatic ductal carcinoma (PDAC) with peritoneal metastasis remains dismal. Systemic chemotherapy alone may not be effective, and the combination of intraperitoneal chemotherapy with systemic chemotherapy is expected to prolong the overall survival in patients with peritoneal metastasis. We have designed a randomized phase III trial to confirm the superiority of intravenous (i.v.) and intraperitoneal (i.p.) paclitaxel (PTX) with S-1 relative to gemcitabine plus nab-PTX (GnP), which is the current standard therapy for patients with metastatic PDAC. A total of 180 patients will be accrued from 30 i...
Source: Trials - February 5, 2022 Category: Research Source Type: clinical trials
Cryoablation as a Minimally Invasive Alternative to Surgery for Managing Ductal Carcinoma In Situ
Condition: Ductal Carcinoma in Situ Intervention: Procedure: Cryoablation Sponsors: Glendale Adventist Medical Center d/b/a Adventist Health Glendale; Helen Rey Breast Cancer Research Foundation; California Oncology Research Institute; Doterra Healing Hands Foundation Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 1, 2022 Category: Research Source Type: clinical trials
The AUS-PREDICT Registry for DCIS Patients With DCISionRT Testing
Condition: DCIS Intervention: Diagnostic Test: DCISionRT Test Sponsor: PreludeDx Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 8, 2021 Category: Research Source Type: clinical trials
